

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 December 2001 (20.12.2001)

PCT

(10) International Publication Number
WO 01/96864 A2

(51) International Patent Classification⁷: G01N 33/49

John, B. [US/CA]; 664 Old Hillview Road, Kingston,
Ontario K7M 5C6 (CA).

(21) International Application Number: PCT/US01/18611

(74) Agent: MYERS BIGEL SIBLEY & SAJOVEC, P.A.;
P.O. Box 37428, Raleigh, NC 27627 (US).

(22) International Filing Date: 8 June 2001 (08.06.2001)

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 09/591,642 9 June 2000 (09.06.2000) US

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

Published:

(75) Inventors/Applicants (for US only): FISCHER, Timothy, J. [US/US]; 11530 N. Charoleau Drive, Tucson,
AZ 85737 (US). DOWNEY, Colin [GB/GB]; 23 Grieve
Road, Liverpool, Merseyside L10 7NH (GB). NESHEIM,
Mike [US/CA]; 70-1 Place D'Armes, Kingston, Ontario
K7K-6S4 (CA). SAMIS, John, A. [CA/CA]; 253 College
Street, Kingston, Ontario K7L 4M1 (CA). TEJIDOR,
Liliana [US/US]; 10440 Leslie Drive, Raleigh, NC 27615
(US). TOH, Cheng, Hock [MY/GB]; 35 Beaconsfield
Road, Liverpool, Merseyside L25 6EQ (GB). WALKER,

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/96864 A2

(54) Title: A METHOD FOR DETECTING A LIPOPROTEIN-ACUTE PHASE PROTEIN COMPLEX AND PREDICTING AN
INCREASED RISK OF SYSTEM FAILURE OR MORTALITY

(57) Abstract: A method for diagnosing a condition of a patient involves the steps of (a) adding one or more reagents to a test sample from a patient, the test samples comprising at least part of a blood sample from the patient, in order to cause formation of a complex comprising at least one acute phase protein at least one human lipoprotein, while causing substantially no fiber polymerization; (b) measuring the formation of the complex over time so as to derive a time-dependent measurement profile, and (c) determining a slope and/or total change in the time-dependent measurement profile, so as to diagnose a condition of the patient. A greater formation of the complex is correlated to increased probability of death of the patient.

5 A METHOD FOR DETECTING A LIPOPROTEIN-ACUTE PHASE PROTEIN
COMPLEX AND PREDICTING AN INCREASED RISK OF SYSTEM
FAILURE OR MORTALITY

CROSS-REFERENCES TO RELATED APPLICATIONS

10 This application is a continuation-in-part of U.S. patent application 09/244,340 to Toh et al., filed February 4, 1999, and U.S. patent application 09/372,954 to Toh et al., filed August 12, 1999, the subject matter of each being incorporated herein by reference. This 15 application also relates to U.S. patent 5,646,046 to Fischer et. al., the subject matter of which is incorporated herein by reference.

BACKGROUND OF THE INVENTION

20 Blood clots are the end product of a complex chain reaction where proteins form an enzyme cascade acting as a biologic amplification system. This system enables relatively few molecules of initiator products to induce sequential activation of a series of inactive proteins, 25 known as factors, culminating in the production of the fibrin clot. Mathematical models of the kinetics of the cascade's pathways have been previously proposed.

Thrombosis and hemostasis testing is the in vitro study of the ability of blood to form clots and to break 30 clots in vivo. Coagulation (hemostasis) assays began as manual methods where clot formation was observed in a test tube either by tilting the tube or removing fibrin strands by a wire loop. The goal was to determine if a patient's blood sample would clot after certain materials 35 were added. It was later determined that the amount of time from initiation of the reaction to the point of clot formation in vitro is related to congenital disorders,

acquired disorders, and therapeutic monitoring. In order to remove the inherent variability associated with the subjective endpoint determinations of manual techniques, instrumentation has been developed to measure clot time, 5 based on (1) electromechanical properties, (2) clot elasticity, (3) light scattering, (4) fibrin adhesion, and (5) impedance. For light scattering methods, data is gathered that represents the transmission of light through the specimen as a function of time (an optical 10 time-dependent measurement profile).

Two assays, the PT and APTT, are widely used to screen for abnormalities in the coagulation system, although several other screening assays can be used, e.g. protein C, fibrinogen, protein S and/or thrombin time. 15 If screening assays show an abnormal result, one or several additional tests are needed to isolate the exact source of the abnormality. The PT and APTT assays rely primarily upon measurement of time required for clot time, although some variations of the PT also use the 20 amplitude of the change in optical signal in estimating fibrinogen concentration.

Blood coagulation is affected by administration of drugs, in addition to the vast array of internal factors and proteins that normally influence clot formation. For 25 example, heparin is a widely-used therapeutic drug that is used to prevent thrombosis following surgery or under other conditions, or is used to combat existing thrombosis. The administration of heparin is typically monitored using the APTT assay, which gives a prolonged 30 clot time in the presence of heparin. Clot times for PT assays are affected to a much smaller degree. Since a number of other plasma abnormalities may also cause prolonged APTT results, the ability to discriminate between these effectors from screening assay results may 35 be clinically significant.

The present invention was conceived of and developed for predicting haemostatic dysfunction in a sample based

on one or more time-dependent measurement profiles, such as optical time-dependent measurement profiles. In addition, the present invention is directed to predicting the presence of Disseminated Intravascular Coagulation in 5 a patient based on a time-dependent profile, such as an optical transmission profile, from an assay run on the patient's blood or plasma sample.

SUMMARY OF THE INVENTION

10 The present invention is directed to a method for detecting a precipitate in a test sample in the absence of clot formation. The method includes providing a test sample and adding thereto a reagent, the reagent alone or in combination with additional reagents causing the 15 formation of a precipitate. The reagent preferably comprises a metal divalent cation and optionally includes a clot inhibiting substance. The detection of the precipitate can be qualitative or quantitative, and the precipitate can be detected such as by a clotting assay, 20 a latex agglutination or gold sol assay, an immunoassay such as an ELISA, or other suitable method that would allow for detection and/or quantitation of the precipitate. The formation of the precipitate can be detected as an endpoint value, or kinetically. This 25 precipitate detection allows for predicting Haemostatic Dysfunction in patients. The present invention is useful for predicting Haemostatic Dysfunction that can lead to bleeding or thrombosis, or specifically to Disseminated Intravascular Coagulation (DIC).

30 More particularly, the present invention is directed to a method comprising adding a reagent to a test sample having at least a component of a blood sample from a patient, measuring the formation of a precipitate due to the reaction of the test sample and the reagent, over time 35 so as to derive a time-dependent measurement profile, the reagent capable of forming a precipitate in the test sample without causing substantial fibrin polymerization.

The invention is also directed to a method for determining whether or not a patient has haemostatic dysfunction, comprising obtaining a blood sample from a patient, obtaining plasma from said blood sample, adding a 5 reagent capable of inducing the formation of a precipitate in patients with haemostatic dysfunction without causing any substantial fibrin polymerization, taking one or more measurements of a parameter of the sample wherein changes in the sample parameter are capable of correlation to 10 precipitate formation if present, and determining that a patient has haemostatic dysfunction if precipitate formation is detected.

The present invention is also directed to a method for determining in a patient sample the presence of a 15 complex of proteins comprising at least one of a 300 kDa protein, serum amyloid A and C-reactive protein, comprising obtaining a test sample from a patient, adding an alcohol, a clot inhibitor, and a metal cation, wherein a precipitate is formed which comprises a complex of 20 proteins including at least one of a 300 kDa protein, serum amyloid A and C-reactive protein.

The invention is also directed to a method comprising adding a coagulation reagent to an aliquot of a test sample from a patient, monitoring the formation of fibrin 25 over time in said test sample by measuring a parameter of the test sample which changes over time due to addition of the coagulation reagent, determine a rate of change, if any, of said parameter in a period of time prior to formation of fibrin polymerization in said test sample, if 30 the determined rate of change is beyond a predetermined threshold, then with a second aliquot of the patient test sample, add thereto a reagent that induces the formation of a precipitate in the absence of fibrin polymerization, measuring the formation of the precipitate over time, and 35 determining the possibility or probability of haemostatic dysfunction based on the measurement of the precipitate.

The invention is also directed to a method for

monitoring an inflammatory condition in a patient, comprising adding a reagent to a patient test sample, the reagent capable of causing precipitate formation in some patient test samples without causing fibrin 5 polymerization, measuring a parameter of the test sample over time which is indicative of said precipitate formation, determining the slope of the changing parameter, repeating the above steps at a later date or time, wherein an increase or decrease in the slope at the 10 later date or time is indicative of progression or regression, respectively, of the inflammatory condition.

The invention is further directed to a method for diagnosing and treating patients with haemostatic dysfunction, comprising adding a reagent to a test sample 15 that causes precipitate formation without causing fibrin polymerization, taking measurements over time of a parameter of the test sample that changes due to the formation of the precipitate, determining the rate of change of said parameter, determining that a patient has 20 haemostatic dysfunction if said rate of change is beyond a predetermined limit; intervening with treatment for said haemostatic dysfunction if said rate of change is beyond the predetermined limit.

The invention also is directed to a method comprising 25 adding a reagent to a patient sample capable of causing formation of a precipitate in said sample, monitoring a changing parameter of said sample over time, said parameter indicative of said precipitate formation, determining the rate of change of said parameter or 30 whether said parameter exceeds a predetermined limit at a predetermined time, repeating the above steps at least once, each time at a different plasma/reagent ratios, measuring the maximum, average and/or standard deviation for the measurements; and determining haemostatic 35 dysfunction based on the maximum, average and/or standard deviation measurements.

The present invention is further directed to an

immunoassay comprising providing a ligand capable of binding to C-reactive protein or the 300 kDa protein in lane 5 of Fig. 21, adding said ligand to a test sample from a patient and allowing binding of said ligand to C-reactive protein or said 300 kDa protein in said test sample, detecting the presence and/or amount of C-reactive protein or said 300 kDa protein in said sample, and diagnosing haemostatic dysfunction in the patient due to the detection and/or amount of C-reactive protein or said 10 300 kDa protein detected.

The invention further relates to a method for testing the efficacy of a new drug on a human or animal subject with an inflammatory condition and/or haemostatic dysfunction, comprising adding a reagent to a patient test 15 sample, said reagent capable of causing precipitate formation in some subject test samples without causing fibrin polymerization, measuring a parameter of said test sample over time which is indicative of said precipitate formation, determining the slope of said changing 20 parameter and/or the value of said parameter at a predetermined time, administering a drug to said animal or human subject, repeating the above steps at a later date or time, wherein an increase or decrease in said slope or value at said later date or time is indicative of the 25 efficacy of said drug.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and 1B illustrate transmittance waveforms on the APTT assay with (A) showing a normal appearance, 30 and (B) showing a biphasic appearance. Clot time is indicated by an arrow.

Figure 2 illustrates transmittance levels at 25 seconds in relation to diagnosis in 54 patients with biphasic waveform abnormalities. The horizontal dotted line 35 represents the normal transmittance level.

Figure 3 illustrates serial transmittance levels (A)) and waveforms on day 1 (B), day 4 (C), and day 6 (D) on a

patient who developed DIC following sepsis and recovered.

Figure 4 illustrates serial transmittance levels (A) and waveforms on day 2 (B), day 5 (C), and day 10 (D) on a patient who developed DIC following trauma and died.

5 Figure 5 illustrates ROC plots for the prediction of DIC transmittance at 25 seconds (TR25), APTT clot time, and slope_1 (the slope up to the initiation of clot formation).

Figure 6 shows a histogram for DIC, normal and 10 abnormal/non-DIC populations for TR25.

Figure 7 shows a histogram for DIC, normal and abnormal/non-DIC populations for Slope_1.

Figure 8 shows group distributions for slope_11.

Figure 9 shows partial subpopulations of the data 15 shown in Figure 8.

Figure 10 shows group distributions for TR25.

Figure 11 shows partial subpopulations of the data shown in Figure 10.

Figure 12 is an optical transmission profile for an 20 APTT assay using Platelin™.

Figure 13 is an optical transmission profile for the PT assay using Recombiplast™.

Figure 14 is an optical transmission profile for the PT assay using Thromborel S™.

25 Figure 15 is a standard curve for ELISA of CRP.

Figure 16 is a graph showing the time course of turbidity in a sample upon adding Ca^{2+} and PPACK compared to samples of normal and patient plasmas mixed in the various proportions indicated to the right. HBS/1 mM 30 citrate was the diluent.

Figure 17 is a graph showing the relationship between maximum turbidity change and amount of patient plasma in a sample.

Figure 18 shows the results of anion exchange 35 chromatography of material recovery after fractionation of patient plasma. Peaks of interest are indicated.

Figures 19 shows non-reduced (A) and reduced (B) SDS-

PAGE of various fractions of patient plasma.

Figure 20 shows immunoblots of CRP in normal (A and B) and DIC plasma (C). In (A) and (B) lanes are labelled with the patient number; (C) is labeled with the ng amount 5 of CRP loaded.

Figure 21 illustrates the turbidity change upon adding divalent calcium to materials obtained upon Q-sepharose chromatography in the absence of plasma (except top curve).

10 Figure 22 shows the response to increasing calcium concentrations in optical transmission profiles. Profiles are shown for two normal patients (A, B) and two patients with DIC (C, D).

15 Figure 23 shows optical transmission profiles for calcium chloride alone (B) or in combination with APTT reagent (A). Numbers indicate patient ID numbers.

Figure 24 is a calibration curve with heparin;

Figure 25 shows CRP levels in 56 ITU patients plotted against transmittance at 18 seconds.

20 Figure 26 shows more samples with CRP and decrease in transmittance at 18 seconds (10000- TR18).

25 Figure 27 depicts a reconstitution experiment showing the effect on turbidity of combining VLDL and CRP (Peak 3), compared to VLDL alone. The starting concentration of VLDL for this experiment was 0.326 mg/mL.

Figure 28 depicts a reconstitution experiment showing the effect on turbidity of combining IDL and CRP (Peak 3) compared to IDL alone. The starting concentration of IDL for this experiment was 0.06797 mg/mL.

30 Figure 29 depicts a reconstitution experiment showing the effect on turbidity of combining LDL and CRP compared to LDL alone and CRP (Peak 3) alone. The starting concentration of LDL for this experiment was 0.354 mg/mL.

35 Figure 30 depicts a reconstitution experiment showing the effect on turbidity of combining HDL and CRP (Peak 3) as compared to HDL alone. The starting concentration of HDL for this experiment was 1.564 mg/mL.

Figure 31 is a ROC plot of sensitivity vs. specificity.

Figure 32 is an immunoblot for apo(B)-100. Lane 1 is protein isolated from normal human plasma, lanes 2-5 are 5 protein samples isolated from DIC patient plasma, and lanes 6-9 are calcium precipitates of protein samples from the same DIC patients in lanes 2-5. The monoclonal apo(B)-100 antibody was used at a 1/5000 dilution. Proteins were visualized with ECL reagents.

10 Figure 33 is an SDS-PAGE gel of calcium precipitates from 4 DIC patients electrophoresed under reducing (lanes 1-4) or non-reducing (lanes 5-8) conditions. Approximately 5 μ g of protein were loaded from patient #1 (lanes 1 and 5), patient #2 (lanes 2 and 6), patient #3 15 (lanes 3 and 7), and patient #5 (lanes 4 and 8). After electrophoresis, the gel was stained with Coomassie Blue, destained, and dried.

Figure 34 is an illustration of peaks 1 and 3 recovered from a Q-Sepharose column of washed calcium 20 precipitate.

Figure 35 is a graph depicting the turbidity changes associated with the addition of excess CRP and Ca^{++} to isolated lipoproteins from normal plasma.

Figure 36 is a graph depicting the quantitation of 25 the interaction between CRP and VLDL. Recombinant CRP and normal VLDL were mixed at various concentrations in buffer and maximum turbidity changes were then recorded after adding Ca^{2+} . The VLDL concentrations (measured as cholesterol) were: 0.030 mM (squares), 0.065 mM 30 (triangles), 0.10 mM (diamonds), and 0.15 mM (circles). The lines are regression lines.

Figure 37 is a graph depicting the quantitation of the interaction between CRP and VLDL. Recombinant CRP and normal VLDL were mixed at various concentrations in 35 lipoprotein deficient plasma and maximum turbidity changes were then recorded after adding Ca^{++} . The VLDL concentrations (measured as cholesterol) were: 0.030 mM

(squares), 0.065 mM (triangles), 0.10 mM (diamonds), and 0.15 mM (circles). The lines are regression lines.

Figure 38 is a graph depicting the calcium concentration dependence of formation of the VLDL/CRP complex. Complex formation is half maximal at 5.0 mM calcium.

Figure 39 is a graph depicting the turbidity changes associated with varying concentrations of VLDL in the presence of excess CRP in buffer and in lipoprotein-deficient plasma.

Figure 40 is a graph depicting the inhibition of VLDL/CRP complex formation by EACA. The IC₅₀ for inhibition by EACA is 2.1 mM.

Figure 41 is a graph depicting turbidity change versus varying CRP concentration.

Figure 42 is a graph depicting correlations between the level of CRP in complex with VLDL and the turbidity change upon recalcification of patient plasma samples. The total concentration of CRP and VLDL (cholesterol) in 20 15 patient plasmas were measured. The level of CRP in complex was calculated, using the parameters for complex formation measured in lipoprotein depleted normal plasma, supplemented with normal VLDL and recombinant CRP. The absorbance change at 405 nm (turbidity) was measured 20 25 minutes after adding CaCl₂ and the thrombin inhibitor PPACK to the samples.

Figure 43 is a graph depicting the correlation between the VLDL levels and turbidity changes upon recalcification of patient plasma versus varying VLDL 30 concentration.

Figure 44 is a graph depicting MDA waveforms for normal, bi-phasic, and bi-phasic/thrombin inhibitor samples.

Figure 45 is non-reducing SDS-PAGE gel of isolated 35 precipitate before and after anion exchange chromatography. Lanes 1-3 were loaded with the starting material, peak 1, and peak 3, respectively.

Figure 46 are non-reducing SDS-PAGE gels that were immunoblotted and probed with either anti-APO(B) (A), anti-CRP (B), or anti-SAA (C) antibody. The blots represent the analysis of isolated precipitate before and 5 after anion exchange chromatography. Lanes 1-3 were loaded with the starting material, peak 1, and peak 3, respectively.

Figure 47 is a graph depicting the turbidity changes associated with the a mixture of peaks 1 and 3 isolated 10 from anion exchange chromatography.

Figure 48 is a graph showing the time course of turbidity changes after adding Ca^{++} to mixtures of normal plasma and the plasma of a patient with a biphasic waveform. The values at the right are volumes of patient 15 plasma in a total of 50 μL .

Figure 49 is a graph depicting a standard curve assay of the change in turbidity associated with varying amounts of patient plasma added. 1 mL of patient plasma = 1 unit of activity.

20 Figure 50 is a graph depicting the effect of EACA on Ca^{++} -dependent turbidity changes associated with VLDL and CRP.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

25 In the present invention, not only can a particular abnormality (Haemostatic Dysfunction) be detected, but in addition the progression of the disease can be monitored in a single patient. More particularly, system failure and/or mortality can be predicted. Haemostatic Dysfunction, as used herein, is a condition evidenced by 30 the formation of a precipitate (prior to or in the absence of clot formation), depending upon the reagent used).

Disseminated intravascular coagulation (DIC - a type of Haemostatic Dysfunction) prognosis has been hampered by 35 the lack of an early, useful and rapidly available diagnostic marker. The invention has been found to be not only useful as an early diagnostic and single monitoring

marker of DIC, but in addition the quantifiable and standardizable changes also allow for prognostic applicability in clinical management.

Disseminated intravascular coagulation (DIC) is a 5 secondary response to a pre-existing pathology whereby the haemostatic response becomes perturbed and disseminated as opposed to the focused events of normal haemostasis. Despite improvements both in the intensive care management of patients and in our basic knowledge of haemostatic 10 mechanisms in DIC, survival in this patient group is still very discouraging. Fundamental to the management of this complication is the implementation of aggressive therapy directed at forestalling or eradicating the primary pathology as the source of the initiating stimulus. 15 However, in practical terms, the problem remains one of early identification of DIC to facilitate immediate and appropriate intervention. Although the technological armory available to the clinical investigator has expanded enormously, the pace of acute DIC precludes most of the 20 more specific tests and reliance is still placed on traditional screening tests such as the prothrombin (PT), activated partial thromboplastin time (APTT) and platelet count. These tests lack specificity on an individual basis and are only useful in DIC if they lead on to 25 further determinations of fibrinogen and fibrin breakdown products/D-dimers. However, changes in these parameters may not occur all at the same time and as such, serial testing is often needed which inevitably leads to a delay in diagnosis and clinically useful intervention.

30 The normal sigmoidal appearance from an APTT transmittance waveform (TW) changes to a "bi-phasic" appearance in DIC patients. This represents a loss in the plateau of a normal APTT-TW, with development of an initial low gradient slope followed by a much steeper 35 slope (Figures 1a and b). In addition, this bi-phasic pattern can be seen even when the APTT clotting time result is normal.

Freshly collected blood samples that required a PT or an APTT were analyzed prospectively over a two week working period. These were in 0.105 M tri-sodium citrate in the ratio of 1 part anticoagulant to 9 parts whole 5 blood and the platelet-poor plasma was analyzed on the MDA (Multichannel Discrete Analyzer) 180, an automated analyzer for performing clinical laboratory coagulation assays using an optical detection system (Organon Teknika Corporation, Durham, NC, USA). In addition, to deriving 10 the clot times for both PT (normal 11.2-15s) using MDA Simplastin LS™ and APTT (normal 23-35s) using MDA Platelin LS™ with 0.025M calcium chloride (Organon Teknika Corporation, USA), an analysis of the TW for the APTT was performed on each occasion at a wavelength of 580nm. To 15 quantitate the visual profile, the amount of light transmittance at 25 seconds was recorded. A normal waveform has a light transmittance of 100% that is represented on the analyzer and in Figure 1a without the decimal point as 10000. As such, a bi-phasic change will 20 have a reduced light transmittance of less than 10000. As can be seen in Figure 1B, decreasing levels of light transmittance prior to clot formation correlate directly with increasing steepness of the bi-phasic slope. The recording of the light transmittance at 25 seconds also 25 allows for standardization between patients and within the same patient with time. If the minimum level of light transmittance for each sample were to be used instead, this would be affected by variations in the clot time of the APTT and would therefore not be ideal for comparisons.

30 To ensure that no cases of DIC were overlooked, the following criteria was followed. If (a) an abnormal bi-phasic TW was encountered, or (b) a specific DIC screen was requested, or (c) if there was a prolongation in either the PT or APTT in the absence of obvious 35 anticoagulant therapy, a full DIC screen was performed. This would further include the thrombin time (TT) (normal 10.5-15.5 seconds), fibrinogen (Fgn) (normal 1.5-3.8 g/l)

and estimation of D-dimer levels (normal < 0.5 mg/l) on the Nyocard D-Dimer (Nycomed Pharma AS, Oslo, Norway). Platelet counts (Plt) (normal 150-400 $10^9/l$) performed on an EDTA sample at the same time were recorded. In 5 addition, clinical details were fully elucidated on any patient with a bi-phasic TW or coagulation abnormalities consistent with DIC.

The diagnosis of DIC was strictly defined in the context of both laboratory and clinical findings of at 10 least 2 abnormalities in the screening tests (increased PT, increased APTT, reduced Fgn, increased TT or reduced Plt) plus the finding of an elevated D-dimer level (>0.5 mg/l) in association with a primary condition recognized in the pathogenesis of DIC. Serial screening tests were 15 also available on those patients to chart progression and confirmation of the diagnosis of DIC as was direct clinical assessment and management. For statistical analysis, values for the sensitivity, specificity, positive and negative prediction of the APTT-TW for the 20 diagnosis of DIC were calculated employing a two-by-two table. 95% confidence intervals (CI) were calculated by the exact binomial method.

A total of 1,470 samples were analyzed. These were from 747 patients. 174 samples (11.9%) from 54 patients 25 had the bi-phasic waveform change. 22 of these 54 patients had more than 3 sequential samples available for analysis. DIC was diagnosed in 41 patients with 30 of these requiring transfusion support with fresh frozen plasma, cryoprecipitate or platelets. The underlying 30 clinical disorders as shown in Table 1.

TABLE 1

	<u>Disorder</u>	<u>No</u>
5	Infections	17
	Trauma or recent major surgery	16
	Malignancy	2
	Hepatic Disease	1
10	Obstetric	1
	Miscellaneous Additional Causes *	4

15 * Includes hypoxia, acidosis, Lithium overdosage and graft rejection

40 of the 41 patients with DIC had the bi-phasic TW. The one false negative result (DIC without a bi-phasic TW) 20 occurred in a patient with pre-eclampsia (PET) where the single sample available for analysis showed a prolonged PT of 21.0s, APTT of 44.0s and raised D-dimers of 1.5mg/l. 5 other patients were identified in this study with PET and none had either DIC or a bi-phasic TW. Of the 14 patients 25 with a bi-phasic TW which did not fulfil the criteria of DIC, all had some evidence of a coagulopathy with abnormalities in one or two of the screening tests. These abnormal results fell short of the criterion for DIC as defined above. 4 of these 14 patients had chronic liver 30 disease with prolonged PT and mild thrombocytopenia. A further 2 patients had atrial fibrillation with isolated elevation of D-dimer levels only. The remaining 8 patients were on the ICU with multiple organ dysfunction arising from trauma or suspected infection but without the 35 classical laboratory changes of DIC. These patient profiles were described in the ICU as consistent with the "systemic inflammatory response syndrome" (SIRS). Based on these figures, the bi-phasic TW has a 97.6% sensitivity

for the diagnosis of DIC with a specificity of 98%. Use of an optical transmittance waveform was found to be helpful in detecting the biphasic waveform.

5

TABLE 2

		Biphasic	Normal	Total
		TW	TW	
10	DIC Positive	40	1	41
	DIC Negative	14	692	706
Total		54	693	747

15 Sensitivity 97.6% (Cl 85.6-99.99%), Specificity 98.0% (Cl 96.6-98.9%), Positive predictive value 74.0% (Cl 60.1-84.6%), Negative predictive value 99.9% (Cl 99.1-99.99%)

20 The positive predictive value of the test was 74%, which increased with increasing steepness of the bi-phasic slope and decreasing levels of light transmittance (Table 2 and Figure 2). In the first two days of the study, there were 25 plus elevation of D-dimer levels. These were patients who were clinically recovering from DIC that occurred in the week preceding the study. This led to the impression that TW changes might correlate more closely with clinical events than the standard markers of DIC.

30

TABLE 3

Day	Time	PT (11.2- 15s)	APTT (23-35s)	TT (10.5- 15.5s)	Fgn (1.5- g/l)	D- Dimer (<0.5 mg/l)	Plt (150- 400x 10 ⁹ /l)	TW
1	0923	14.7	32.9	12.0	4.7	0.00	193	B*
1	2022	20.8*	38.6*	12.4	5.7	6.00*	61*	B*
2	0920	18.0*	33.0	13.0	5.2	2.00*	66*	N
3	1011	16.3*	24.8	13.2	4.7	0.00	64*	N

PT=Prothrombin time, APTT=Activated Partial Thromboplastin Time,
 5 TT=Thrombin Time, Fgn=Fibrinogen, PTT=Platelet count,
 TW=Transmittance Waveform
 *Indicates abnormal changes, B=bi-phasic, N=normal

10 The availability of more than 3 sequential samples in
 22 patients allowed for further assessment. Table 3
 illustrates one such example with serial test results from
 a patient with *E. coli* septicaemia.

15 The appearance of a bi-phasic TW preceded changes in
 the standard tests for the diagnosis of DIC. It was only
 later in the day that the PT, APTT, Plt and D-dimer levels
 became abnormal and fulfilled the diagnostic criteria of
 DIC. Treatment with intravenous antibiotics led to
 20 clinical improvement by Day 2 with normalization of her TW
 in advance of the standard parameters of DIC. D-dimers
 and Plt were still respectively abnormal 24 and 48 hours
 later.

25 This correlation between clinical events and TW
 changes was seen in all the DIC patients where samples
 were available to chart the course of clinical events. As
 the TW changes were quantifiable and standardizable
 through recording of the transmittance level at 25
 seconds, this analysis provided a handle in assessing
 prognostic applicability. Figure 3 illustrates the
 30 results of a patient who initially presented with
 peritonitis following bowel perforation. This was further
 complicated by gram negative septicaemia post-operatively

with initial worsening of DIC followed by a gradual recovery after appropriate therapy. As DIC progressed initially, there was increasing steepness in the bi-phasic slope of the TW and a fall in the light transmittance level. A reversal of this heralded clinical recovery. 5 Figure 4 illustrates the results of a patient who sustained severe internal and external injuries following a jet-ski accident. Although initially stabilized with blood product support, his condition deteriorated with 10 continuing blood loss and development of fulminant DIC. The bi-phasic slope became increasingly steep with falls in transmittance level as the consequences of his injuries proved fatal.

As DIC can arise from a variety of primary disorders, 15 the clinical and laboratory manifestations can be extremely variable not only from patient to patient but also in the same patient with time. There is therefore, a need for systems that are not only robust in their diagnosis but simple and rapid to perform. Although it 20 has been shown that the bi-phasic TW appeared to be sensitive for Haemostatic Dysfunction (e.g. DIC) and was not seen in other selected patient groups with coagulation aberrations or influenced by either (i) pre-analytical variables, (ii) different silica-based APTT reagents, 25 (iii) the use of thrombin as the initiator of the coagulation reaction or (iv) treatment in the form of heparin or plasma expanders, the robustness of this assay for DIC could only be addressed through a prospective study. This study has shown that the bi-phasic TW 30 provides diagnostic accuracy in DIC with an overall sensitivity of 97.6% and specificity of 98%. In contrast, none of the standard parameters on an individual basis (i.e., PT, APTT, TT, Fgn, Plt, D-dimers) or even in combination, has ever reached the degree of sensitivity or 35 specificity. The ready availability of TW data from the MDA-180 would also fulfil the criteria of simplicity and rapidity unlike the measurements of thrombin-antithrombin

complexes or other markers that are dependent on ELISA technology. In addition, the advantages of TW analysis are that: (a) the bi-phasic TW change appears to be the single most useful correlate within an isolated sample for 5 DIC and as such, reliance need no longer be placed on serial estimations of a battery of tests, and (b) the appearance or resolution of the bi-phasic TW can precede changes in the standard, traditional parameters monitored in DIC with strong, clear correlation to clinical events 10 and outcome.

Although the bi-phasic TW was also seen in patients who did not have DIC *per se* as defined by the above criteria, the clinical conditions were associated with Haemostatic Dysfunction - namely activated coagulation 15. prior to initiation of clot formation resulting in a biphasic waveform (for example in chronic liver disease or in the very ill patients on the Intensive Care Unit who had multiple organ dysfunction). It appears that bi-phasic TW is sensitive to non-overt or compensated DIC and 20 that a transmittance level of less than 90% (Figure 2) or sequential falls in that level (Figure 4), reflects decompensation towards a more overt manifestation and potentially fulminant form of DIC. This line of explanation is supported by the observation of only a mild 25 bi-phasic TW (transmittance level of about 95%) in 2 patients with atrial fibrillation; a condition that is associated with mild coagulation activation and elevated D-dimer levels. As no follow-up samples were available on these 2 patients whose clinical details were otherwise 30 unremarkable, their bi-phasic TW could well have been transient. Nonetheless, these cases illustrate that the lower the level of light transmittance, the more likely the bi-phasic TW becomes predictive of Haemostatic Dysfunction, particularly DIC.

35 The observation of a normal TW in a patient with PET and DIC needs further exploration as the study did not selectively aim to examine any particular patient groups

and only had a total of 6 patients with PET; the remaining 5 of which did not have DIC. One explanation which would be supported by other findings in this study is that the patient could have been recovering from PET and DIC at the 5 time of the sample. There may already have been normalization in the bi-phasic TW in advance of the other parameters which were still abnormal and indicative of DIC. Another explanation is that the disturbed haemostatic process in PET is more localized and different 10 from the DIC that arises from other conditions. Such patients respond dramatically to delivery of the fetus which suggests anatomical localization of the pathological process to the placenta despite standard laboratory clotting tests implying systemic evidence of the 15 condition.

Example:

Though analysis of the transmittance at a time of 25 seconds is helpful in predicting DIC, a second embodiment of the invention has been found that greatly improves 20 sensitivity and specificity. It has been found that looking at transmittance at a particular time can result in detecting an artifact or other decrease in transmittance at that point, even though the waveform is not a bi-phasic waveform. For example, a temporary dip in 25 transmittance at 25 seconds would cause such a patient sample to be flagged as bi-phasic, even if the waveform was normal or at least not bi-phasic. Also, if a patient sample had a particularly short clotting time, then if 30 clot formation begins e.g. prior to 25 seconds (or whatever time is preselected), then the waveform could be flagged as biphasic, even though the real reason for decreased transmittance at 25 seconds is because clot formation has already begun/occurred.

For this reason, it has been found that rather than 35 analysis of transmittance at a particular time, it is desirable to calculate the slope of the waveform prior to initiation of clot formation. This calculation can

involve determination of clot time followed by determination of waveform slope prior to clot time. In an additional embodiment, the slope (not transmittance) is determined prior to clot time or prior to a preselected time period, whichever is less. As can be seen in Figure 11, when transmittance is used for determining e.g. DIC, there is poor specificity and sensitivity. However, as can be seen in Figure 9, when slope prior to initiation of clot formation is used, specificity and sensitivity are greatly improved, and are better than standard tests used in the diagnosis of Haemostatic Dysfunction, such as DIC.

Additional testing was performed on three sets of patients. The first set consisted of 91 APTT assays run on samples from 51 different confirmed DIC patients. The second set of data consisted of 110 APTT assays run on samples from 81 different confirmed normal patients. The third set of data included 37 APTT assays run on 22 abnormal, non-DIC samples. Figure 5 illustrates ROC plots for the prediction of DIC for three different parameters derived from the APTT assay using the combined data sets described: (1) transmittance at 25 seconds (TR25), (2) APTT clot time, and (3) slope 1 (the slope up to initiation of clot formation). Slope 1 exhibited the best predictive power, followed by TR25. It has also been shown that transmittance at 18 seconds has predictive value, particularly when the APTT clot time is less than 25 seconds. The "cutoffs" associated with the highest efficiency for the three parameters are listed in Table 4:

Table 4

Parameter	Cutoff
TR25	< 9700
Clot Time	> 35
Slope 1	< -0.0003

30

It should be noted that these cutoffs have shifted with the addition of the third set, and would likely shift again, depending on the sample populations. Figures 6 and

7 show the histograms for the DIC, normal and abnormal/non-DIC populations for TR25 and slope 1 respectively. Tables 5 and 6 show the data for the histograms in Figures 6 and 7 respectively:

5

TABLE 5

Bins	DIC	Normal	Abnormal/Non-DIC
-0.006	3	0	0
-0.005	2	0	0
-0.004	1	0	0
-0.003	10	0	0
-0.002	24	0	0
-0.001	33	0	0
-0.0005	12	0	0
-0.0002	5	5	2
-0.0001	1	37	13
More	0	68	22

TABLE 6

Bin	DIC	Normal	Abnormal/Non-DIC
7000	34	1	0
8000	18	2	0
9000	26	6	1
9500	8	3	0
9600	3	2	1
9700	1	0	0
9800	1	3	0
9900	0	21	4
10000	0	62	30
More	0	10	1

10

Figures 8 and 10 show the group distributions for Slope 1 and TR25 respectively; and Figures 9 and 11 show the group distributions for Slope 1 and TR25 respectively. 5 Figures 9 and 11 show partial subpopulations of the data shown in Figures 8 and 10.

When the prediction of Haemostatic Dysfunction is performed on an automated or semi-automated analyzer, the detected bi-phasic waveform can be flagged. In this way, 10 the operator of the machine, or an individual interpreting the test results (e.g. a doctor or other medical practitioner) can be alerted to the existence of the biphasic waveform and the possibility/probability of Haemostatic Dysfunction such as DIC. The flag can be 15 displayed on a monitor or printed out. A slope of less than about -0.0003 or less than about -0.0005 is the preferred cutoff for indicating a bi-phasic waveform. An increasing steepness in slope prior to clot formation correlates to disease progression.

20 The above examples show that waveform analysis on the APTT assay can identify characteristic bi-phasic patterns in patients with haemostatic dysfunction. In the majority of cases, this dysfunction could be labelled as DIC. This diagnostic waveform profile was seen in all 25 APTT reagents tested, which were either silica or ellagaic acid-based. It has also been surprisingly found that a bi-phasic waveform can also be seen on PT assays with particular reagents, and that the bi-phasic waveform is likewise indicative of haemostatic dysfunction, primarily 30 DIC.

Using samples that give bi-phasic APTT waveforms, the PT waveform profile was derived using PT reagents (thromboplastin), namely Recombiplast™ (Ortho), Thromborel™ (Dade-Behring) and Innovin™ (Dade-Behring). 35 Both Recombiplast™ and Thromborel™ were particularly good at showing bi-phasic responses. Innovin™ was intermediate in its sensitivity. Using the transmittance level at 10

seconds into the PT reaction as the quantitative index, Recombiplast™ and Thromborel™ objectively showed lower levels of light transmittance than Innovin™. Thromborel™ can show a slight increase in initial light transmittance 5 before the subsequent fall. This may be, in part, related to the relative opaqueness of Thromborel™.

Further studies were performed comparing APTT profiles using Platelin™ and PT waveform profiles using Recombiplast™. Consecutive samples over a four week 10 period from the intensive care unit were assessed. Visually, and on objective scores (comparing TL18 for APTT and TL10 for PT), the APTT profile was more sensitive to changes of haemostatic dysfunction and clinical 15 progression than the PT profile. This relative sensitivity can be seen in the APTT profile of Figure 12 (Platelin) compared to the PT profiles of Figure 13 (Recombiplast) and Figure 14 (Thromborel S). Invariably, at smaller changes in light transmittance, the APTT waveform detected abnormalities more easily than the PT 20 waveform. Nonetheless, in severe degrees of haemostatic dysfunction, both bi-phasic profiles were concordant.

In a further embodiment of the invention, the time dependent measurement, such as an optical transmittance profile, can be performed substantially or entirely in the 25 absence of clot formation. In this embodiment, a reagent is added which causes the formation of a precipitate, but in an environment where no fibrin is polymerized. The reagent can be any suitable reagent that will cause the formation of a precipitate in a sample from a patient with 30 haemostatic dysfunction, such as DIC. As an example, divalent cations, preferably of the transition elements, and more preferably calcium, magnesium, manganese, iron or barium ions, can be added to a test sample. These ions cause activation of an atypical waveform that can serve as 35 an indicator of haemostatic dysfunction. It is also possible to run this assay in the absence of a clotting reagent (APTT, PT, or otherwise). As part of the reagent

that comprises the activator of the atypical waveform, or separately in another reagent, can also be provided a clot inhibitor. The clot inhibitor can be any suitable clot inhibitor such as hirudin, PPACK, heparin, antithrombin, 5 I2581, etc. The formation of the atypical waveform can be monitored and/or recorded on an automated analyzer capable of detecting such a waveform, such as one that monitors changes in turbidity (e.g. by monitoring changes in optical transmittance).

10 **Figure 44** is an illustration of two waveforms: waveform (triangles) is a test run on a sample using an APTT clotting reagent and resulting in an atypical (biphasic) waveform, whereas waveform (squares) is a test run on a sample where a clot inhibitor is used (along with 15 a reagent, such as a metal divalent cation, which causes the formation of a precipitate in the sample). Waveform (squares) is exemplary of a waveform that can result in patients with haemostatic dysfunction where no clotting reagent is used and/or a clot inhibitor is added prior to 20 deriving the time-dependent measurement profile. Generally speaking, the greater the slope of the waveform (the larger the drop in transmittance in the same period of time) due to the precipitate formation, the greater severity of the patient's haemostatic dysfunction. **Figure 25 15** is a standard curve for ELISA of CRP (CRP isolated from 25 a patient used as the standard).

The precipitate formed in the present invention was isolated and characterized by means of chromatography and purification. Gel Filtration was performed as follows: A 30 column (Hiprep Sephadryl S-300 High resolution - e.g. resolution of 10 to 1500 kDa) was used. The volume was 320 ml (d=26mm, l=600mm), and the flow rate was 1.35 ml/min.

Figure 16 is a graph showing the time course of 35 turbidity in a sample upon adding a precipitate inducing agent (in this case divalent calcium) and a thrombin inhibitor (in this case PPACK) to mixtures of patient and

normal plasmas. **Figure 17** is a graph showing the relationship between maximum turbidity change and amount of patient plasma in one sample. 0.05 units implies 100% patient plasma.

5 The steps used in the purification of components involved in the turbidity change in a patient's plasma were as follows: PPACK (10 μ M) was added to patient plasma. Calcium chloride was added to 50mM, followed by 8 minutes of incubation, followed by the addition of ethanol 10 to 5%. The sample was then centrifuged 10,500 \times g for 15 minutes at 4 degrees Celsius. The pellet was then dissolved in HBS/1mM citrate/10 μ M PPACK, followed by 35-15 $\text{NH}_4\text{}_2\text{SO}_4$ fractionation. Finally, an ion exchange 15 NaCl gradient and 50ml/side, to collect 2ml fractions.

Figure 18 shows the results of anion exchange chromatography (Q-sepharose) of material recovered after the 35-70% ammonium sulfate fractionation of patient plasma.

20 **Figures 19A** and **19B** show the non-reduced and reduced, respectively, SDS-PAGE of various fractions obtained upon fractionation of patient plasma. The loading orientation (left to right): 5-15% gradient/Neville Gel. (approximately 10 μ g protein loaded per well). In lane 1 are molecular weight standards (94, 67, 45, 30, 20 and 14 25 kDa from top to bottom. In lane 2 is 35% $\text{NH}_4\text{}_2\text{SO}_4$ pellet, whereas in lane 3 is 70% $\text{NH}_4\text{}_2\text{SO}_4$ supernate. Lane 4 is Q-sepharose starting material. Also shown in **Figures 19A** and **19B** are (from **Figure 18**) peaks 1, 2a, 2b and 3 in, 30 respectively, lanes 5, 6, 7 and 8. Lane 9 is pellet 1, whereas in lane 10 are again, molecular weight standards. Results of NH₂-terminal sequencing showed peak 3, the 22 35 kDa protein in lanes 8 and 9 to be C-reactive protein (CRP), and the 10 kDa protein in lane 9 to be human serum amyloid A (SAA). Peak 1 in lane 5 is a >300 kDa protein which, as can be seen in **Figure 21**, is part of the complex of proteins (along with CRP) in the precipitate formed due

to the addition of a metal divalent cation to a plasma sample.

Immunoblots of CRP were performed in normal (NHP) and DIC plasma. Blot A (see **Figure 20**): (used 0.2 μ l plasmas for reducing SDS-PAGE/CRP Immunoblotting). Loading orientation (left to right): NHP; Pt 5; 3; 1; 2; 4; and 8. For Blot B: Loading orientation (left to right): NHP; Pt 9; 10; 11; 7; 6; 12. For Blot C: (CRP purified from DIC patient plasma) - Loading orientation (left to right; ng CRP loaded): 3.91; 7.81; 15.625; 31.25; 62.5; 125; 250. The Blots were blocked with 2% (w/v) BSA in PBS, pH 7.4 and then sequentially probed with rabbit anti-human CRP-IgG (Sigma, Cat# C3527, dil 1:5000 in PBS/0.01% Tween 20) and then treated with the test detecting antibody conjugated to HRP (dil 1:25000 in PBS/0.01% Tween 20).

Figure 21 illustrates the turbidity changes upon adding divalent calcium to materials obtained upon Q-sepharose chromatography in the absence of plasma. No single peak gave a positive response, but a mixture of peak 1 and peak 3 materials did give a positive response indicating the involvement of CRP, a 300 kDa protein, and one or more other proteins in the precipitate (peak 3 + plasma was the control). **Table 7** is a table shows CRP amounts in μ g/ml as determined by ELISA. Delta A405nm is the maximum turbidity change observed when patients' plasmas were recalcified on the presence of the thrombin inhibitor PPACK). **Table 7**, therefore, shows that patients with increased absorbance have varying elevated levels of CRP, once again indicating that more than one protein is involved in the precipitate formation.

TABLE 7

Plasma Sample	[CRP], $\mu\text{g/mL}$	$\Delta 405 \text{ nm}$
Normal Human Pool	0.73	0
Pt #1	248	0.329
Pt #2	277	0.235
Pt #3	319	0.345
Pt #4	443	0.170
Pt #5	478	0.640
Pt #6	492	0.230
Pt #7	528	0.140
Pt #8	576	0.640
Pt #9	600	0.390
Pt #10	639	0.160

5 In one embodiment of the invention, the reagent to plasma ratio is varied between multiple tests using a reagent that induces precipitate formation. This variance allows for amplifying the detection of the precipitate formation by optimization of reagent to plasma ratio (e.g. 10 varying plasma or reagent concentrations). In the alternative, the slope due to the precipitate formation can be averaged between the multiple tests. As can be seen in Figure 22, the response to increasing calcium concentrations is shown in optical transmission waveform 15 profiles. Panels A and B show two normal patients where calcium concentrations were varied (no clotting agents used), whereas the panels C and D show two patients with haemostatic dysfunction (DIC in these two cases) where the metal cation (calcium) concentration was varied (the 20 calcium alone being incapable of any substantial fibrin polymerization).

Though precipitate formation is capable of being detected in patients with haemostatic dysfunction when a clotting agent is used, it is beneficial that the reagent 25 used is capable of forming the precipitate without fibrin

polymerization. As can be seen in **Figure 23**, the slope is more pronounced and more easily detectable when a reagent such as calcium chloride is used alone (panel A) as compared to when it is used along with a clotting reagent such as an APTT reagent (panel B). As can be seen in **Figure 24**, when a clot inhibitor was added (in this case heparin), all parameters including slope_1 gave good results, and slope_1 showed the best sensitivity. For the above reasons, a reagent capable of precipitate formation in the absence of fibrin polymerization and/or a clot inhibitor are preferred.

As can be seen in **Figure 25**, CRP levels from 56 ITU patients were plotted against transmittance at 18 seconds.

The dotted line is the cut-off for an abnormal transmittance at 18 seconds. **Figure 26** shows more samples with CRP and decrease in transmittance at 18 seconds (10000 - TR18). These figures indicate that patients with abnormal transmittance levels due to precipitate formation all have increased levels of CRP. However, not all patients with increased levels of CRP have abnormal transmittance levels thus indicating that more than CRP is involved in the precipitate.

In a further embodiment of the invention, the formation of the precipitate comprising a complex of proteins including CRP is detected and/or quantitated, by the use of a latex agglutination assay. In this method, antibodies are raised against either the 300 kDa protein or CRP. Whether monoclonal or polyclonal antibodies are used, they are bound to suitable latex and reacted with a patient test sample or preferably with the precipitate itself having been separated from the rest of the patient plasma, in accordance with known methods. The amount of agglutination of the latex is proportional to the amount of the CRP complex in the sample.

Alternatively, immunoassays can be performed, such as ELISA's, according to known methods (sandwich, competition or other ELISA) in which the existence and/or

amount of the complex of proteins is determined. For example, an antibody bound to solid phase binds to CRP in the CRP protein complex. Then, a second labeled antibody is added which also binds to CRP in the CRP protein complex, thus detecting the complex of proteins. In the alternative, the second labeled antibody can be specific for the 300 kDa protein in the complex. Or, in a different assay, the antibody bound to solid phase can bind to the 300 kDa protein in the complex, with the second (labeled) antibody binding either to the 300 kDa protein or to CRP. Such immunoassays could likewise be adapted to be specific for SAA. The above techniques are well known to those of ordinary skill in the art and are outlined in Antibodies, A Laboratory Manual, Harlow, Ed 15 and Lane, David, Cold Spring Harbor Laboratory, 1988, the subject matter of which is incorporated herein by reference.

After further studies, it has been determined that the "300 kDa" protein is in fact the Apo(B)-100 compound 20 of VLDL (very low density lipoprotein) having a molecular weight of from 500 to 550 kDa. There can be additional lipoprotein complexes in the precipitate as well, including CRP-LDL (CRP complexed with low density lipoprotein), CRP-IDL (CRP complexed with intermediate 25 density lipoprotein), CRP-chylomicrons, CRP-HDL (CRP complexed with high density lipoprotein) and SAA-VLDL (serum amyloid A complexed with VLDL).

In order to characterize the components of the complex, the precipitate was dispersed in citrate and 30 subjected to anion exchange chromatography (see Figure 34). The procedure yielded two major peaks (referred to hereinafter as "peak 1" and "peak 3"), the first of which was very turbid. The turbidity was obvious to the eye and was quantified by absorbance measurements at 320 nm. 35 Fractions were tested for activity (turbidity formation in normal plasma upon recalcification). Only peak 3 exhibited turbidity when added to normal plasma.

In order to further characterize the precipitated material, lipid and protein analyses were performed. In addition, fractions obtained after anion exchange chromatography were subjected to SDS-PAGE, immunoblotting, 5 and amino acid sequence analysis. The isolated materials were shown to comprise proteins, phospholipids, cholesterol and triglycerides in proportions typical of very low density lipoproteins (VLDL and IDL). See Table 8. Fractionation by anion exchange and SDS-PAGE showed 10 that the precipitate contains Coomassie blue staining protein bands with apparent molecular masses of 500 kDa, 22 kDa and 10 kDa. The 22 kDa protein yielded an amino terminal sequence QTDM₅ KAFV (SEQ ID NO:1), which identified the protein as C-reactive protein. The 10 kDa 15 protein gave two residues at each cycle in the sequenator.

They were consistent with serum amyloid A beginning with amino acids 18 and 19. The 500 kDa species did not yield a sequence, likely due to the small molar amounts of it. The high molecular weight of this band, however, was 20 consistent with apo-lipoprotein B, the major protein component of VLDL.

TABLE 8

Lipoprotein class	Protein	PL	UC	CE	TG
VLDL	10%	15%	6%	14%	53%
IDL	18%	22%	7%	23%	31%
LDL	25%	21%	9%	42%	4%

25

PL=phospholipid, UC=unesterified cholesterol,
CE=cholesteryl esters, TG=triacylglycerol.

After fractionation, the high molecular weight band and SAA were obtained in peak 1, and CRP was obtained in 30 peak 3 (see Figure 34). Peaks 2a and 2b were seen in Figure 18 but not Figure 34 because, in the assay run for Figure 18, the amount of protein and lipoprotein in the sample exceeded the capacity of the column. When the column is not overloaded as in the assay run for Figure

34, peaks 2a and 2b do not appear. The precipitate and materials in peaks 1 and 3 were assessed by immunoblotting for Apo(B)-100, CRP and SAA. The results were consistent with the identification of the 500 kDa material as Apo(B)-5 100, the 22 kDa material as CRP, and the 10 kDa material as SAA.

The starting material, the materials in peaks 1 and 3, and a mixture of them were recalcified in the absence of plasma to determine which component or components were 10 needed for the formation of a precipitate. The results showed that the starting material, but not isolated peak 1 or peak 3 components, formed a precipitate when recalcified. The mixture of peaks 1 and 3, however, did form a precipitate. Therefore, it can be concluded that 15 VLDL and CRP are minimally required to form the precipitate. The procedure was repeated with at least 10 different positive plasmas and the results were the same.

Occasionally, however, SAA was not recovered in the isolated peaks. Nonetheless, precipitates formed with 20 VLDL and CRP in the absence of SAA. It is therefore concluded that SAA can be included in the precipitate/complex, but is not necessary for its formation.

Reconstitution experiments were run to verify the 25 ability of the above-mentioned complexes to form. As can be seen in **Figure 27**, VLDL and P3 (Peak 3 = CRP, see **Figure 18**) at varying concentrations (100/20 μ l: VLDL/CRP and 50/20 μ l VLDL/CRP) shows an increase in absorbance due to turbidity, in comparison with VLDL alone. Likewise, as 30 can be seen in **Figures 28 and 29**, IDL and CRP, as well as LDL and CRP (and to a lesser extent HDL and CRP as can be seen in **Figure 30**) also cause an increase in turbidity when combined together. And, as can be further seen in **Table 9**, the different lipoproteins have different 35 calcium-dependent turbidity activity in the presence of purified CRP.

TABLE 9

Sample	Total Vol Isolated (μ L)	[Protein] (mg/mL)	Excursion (ΔA_{405} nm/ μ L)	Total Protein (mg)	Total Excursion (ΔA_{405} n)
VLDL	900	0.326	0.0096	0.29	8.64
IDL	2000	0.068	0.0018	0.136	3.60
LDL	1500	0.354	0.00033	0.531	0.50
HDL	2000	1.564	0.00028	3.13	0.56

Interestingly, it has been found that the turbidity caused when adding a divalent metal cation such as calcium to patient plasmas which exhibit the characteristic slope (even in the absence of clot formation) due to the above-noted complexes, does not correlate with the level of CRP in the patient plasma. Therefore, the present invention is not directed to detecting CRP levels per se, but rather detecting CRP complexed with lipoproteins (VLDL in particular). In the present invention, it is believed that the formation of the complex *ex vivo* (after adding a divalent metal cation to citrated plasma) corresponds to the existence of the complex *in vivo*, which is possibly an indication of the inability of that patient to clear the formed complex(es). Clearance of VLDL and IDL from the plasma by the liver is directed by their surface apo E. Therefore, if there is defective clearance of the complex(es) from the plasma, it may be due to a mutated, fragmented or otherwise defective apo E, or to an oxidized, mutated or fragmented lipoprotein (e.g. beta-VLDL, an oxidized LDL, an abnormal LDL called Lp(a), or an otherwise abnormal version of VLDL, LDL or IDL). IDL, LDL, Lp(a) and VLDL all have Apo(B)-100, which, if abnormal, may play a role in the improper clearance of the complex(es) from the plasma. Of course a mutated, fragmented or otherwise abnormal form of CRP could also play a role in improper clearance of the complex from plasma, resulting in the characteristic slope in the clot

waveform. As can be seen in Table 10, the change in absorbance due to complex formation does not correlate with the amount of CRP in the patient sample. The level of CRP is not generally limiting in complex formation. In fact, it was found that patients can have elevated levels of CRP and yet their plasmas do not exhibit the waveform slope mentioned herein-above. Adding additional VLDL, however, will cause those samples to undergo a turbidity change (in the presence of certain divalent metal cations such as calcium, of course).

TABLE 10

Plasma Sample	[CRP] $\mu\text{g/mL}$	Change at A405 nm with 0.05U PP
Normal Human Pooled Plasma	3.24	0
Pt #1	204.08	0.359
Pt #2	273.34	0.230
Pt #3	331.47	0.609
Pt #4	333.77	0.181
Pt #5	355.48	0.129
Pt #6	361.81	0.122
Pt #7	389.53	0.308
Pt #8	438.56	0.531
Pt #9	443.62	0.137

15

It has also been found that the detection of precipitate formation correlates to clinical outcome, specifically patient death. Of 529 admissions to an intensive care unit, there were 178 deaths (34% baseline probability of death). The positive predictive value of death increased to 50% when patients had transmittance readings at 18 seconds of 96%, or a slope of -0.00075 or less. This predictive power increased to 77% when transmittance readings at 18 seconds were less than 65% (slope of -0.00432 or less). Using receiver operator

characteristics analysis, the optimum level that maximized predictivity without compromising sensitivity was transmittance at 18 seconds cut-off value of 90% (or slope cut-off value of -0.00132 or less). The predictive value of death at this cut-off was found to be 75%. Additional data is shown in Table 11, where, for patient populations of 10 or more, the positive predictive value generally increases as the negative slope value or transmittance decreases. Thus, not only is the existence of the slope or decreased transmittance a predictor of future clinical outcome (e.g. likelihood of death), but in addition, the greater the formation of the precipitate (the greater the decrease in transmittance or increase in slope), the greater the predictor of the impending death. Figure 31 shows a ROC plot of sensitivity vs. specificity.

TABLE 11

TL 18 ≤ (%)	Slope_1 ≥	Total No. Patients	Total No. Deaths	PPV (%)
96	-0.00075	209	106	51
95	-0.00078	195	101	52
90	-0.00132	131	99	75
85	-0.00184	84	49	58
80	-0.00265	56	35	62
75	-0.00315	35	25	71
70	-0.00370	26	19	73
65	-0.00432	18	14	78
60	-0.00490	12	9	75

Data suggests that 25% of intensive care unit admissions will have a transmittance value at 18 seconds of 90% or less (slope -0.00132 or less) during their clinical course. Thus, the detection of complex formation can be a useful tool in predicting which patients are likely to die (and which in these group are more likely to die than others based on having a more severe decrease in slope or transmittance, and to allow for aggressive

intervention with the hopes of preventing the (likely) impending death. The monitoring of the slope is also a way for monitoring the effects of the intervention.

Therefore, in one embodiment of the invention, the likelihood of system failure or mortality of a patient (e.g. in an intensive care setting) is determined by adding one or more reagents to a test sample from a patient comprising at least a component of a blood sample in order to cause formation of a precipitate comprising an acute phase protein and a lipoprotein. Then, the formation of the precipitate is measured, followed by correlating the formation of the precipitate formation to the likelihood of system failure or mortality of the patient. The method can be performed multiple times (e.g. daily, weekly, etc.) in order to monitor the effectiveness of a patient's therapy. The predictive value of this method alone or in combination with other medical indicators is clearly better than the predictive value without the test. The method also includes measuring the formation of the precipitate over time, such as with an automated analyzer using optical transmittance and/or absorbance. And, the amount of precipitate detected over time (or as a final endpoint) can be correlated to the probability of mortality (the greater the precipitate formation, the greater the likelihood of system failure or mortality, and vice versa). Also, the precipitate formation in this embodiment can form even in the absence of fibrin polymerization.

Figure 32 is a western blot and Figure 33 is an SDS-PAGE gel of calcium precipitates isolated from DIC patients. Figure 32 is a western blot of a 2.5-5% SDS-PAGE gel transferred and probed with a monoclonal antibody to apoB (present on VLDL, IDL and LDL). Lane 1 in Figure 32 is normal human plasma, lanes 2-5 are DIC patient plasma, whereas lanes 6-9 are calcium precipitates from DIC patient plasmas isolated from patients studied in lanes 2-5, respectively. Figure 33 is an 5-15% SDS-PAGE

of calcium precipitates from four DIC patients electrophoresed under reducing (lanes 1-4) and non-reducing (lanes 5-8) conditions. Approximately 5 micrograms of protein was loaded from patient #1 (lanes 5 1,5); patient #2 (lanes 2,6); patient #3 (lanes 3,7) and patient #4 (lanes 4,8). After electrophoresis, the gel was stained in Coomassie Blue, destained and dried. CRP and SAA were identified by immunoblotting and apoB was identified by N-terminal sequencing and immunoblotting.

10 It was also found that the complex formation can be inhibited by phosphorylcholine, or phosphorylcholine with varying fatty acid side chains (e.g. phosphatidylcholine) or vesicles containing phosphorylcholine, phosphorylethanolamine, or phosphylethanolamine with 15 varying fatty acid side chains (e.g. phosphatidylethanolamine) or vesicles containing phosphorylethanolamine, or EACA and the like. It is known that CRP binds directly to PC and that PC competes with lipoproteins for binding to CRP. Phosphatidylcholine was 20 found to be a major phospholipid component in the complex.

PE, apo(A) and sphingomyelin were found to be minor components. It was also found that apo(B) can bind directly to CRP, however this is unlikely to occur *in vivo* (and thus is not likely to be contributing to complex 25 formation) because apo(B) does not appear in plasma in a "free" form unattached to a lipoprotein.

Therefore, in a still further embodiment of the invention, a method is provided which includes adding one or more reagents (which may or may not cause coagulation) 30 to a test sample from a patient in order to cause formation of a precipitate comprising an acute phase protein bound to a lipoprotein. Then, the binding of the acute phase protein to the lipoprotein is measured (either over time or as an endpoint). An inhibiting reagent is 35 added before or after the complex-inducing reagent(s), which inhibiting reagent inhibits at least in part, the binding of the acute phase protein to the lipoprotein.

The extent of inhibition is then determined (e.g. based on the amount of complex formed or not). The inhibiting reagent can be added after all or substantially all of the lipoprotein has become bound to the acute phase protein, 5 or, the inhibiting reagent can be added even prior to adding the complex inducing reagent(s) (e.g. metal divalent cation such as calcium). The types of complex-inhibiting substances can be those such as mentioned above, or an apo-lipoprotein that binds to CRP such as 10 apoB or apoE, or EDTA, sodium citrate, or antibodies to epitopes involved in complex formation. The complex-inhibiting reagent should preferably inhibit, as an example, CRP bound to a chylomicron or chylomicron remnant, or LDL, VLDL or IDL. The method can be performed 15 whereby the complex-causing reagent and/or the complex-inhibiting reagent are added at more than one concentration. This embodiment can be utilized to quantitate the amount of complex and/or establish the specificity of the complex. Due to the correlation of poor 20 clinical outcome and complex formation, in one embodiment, the complex-inhibiting reagent can be used as a therapeutic to decrease the amount of complex in vivo.

Though the primary invention is directed to detecting the complex and thereby predicting mortality, the 25 invention is also directed to detecting total lipoprotein(s) that bind to CRP (and thus determining a total amount of certain lipoproteins in the sample). More specifically, an acute phase protein (such as CRP) is added to a test sample along with precipitate induces such 30 as a divalent metal cation or a reagent to lower the pH at least below 7. The exogenous acute phase protein ensures that substantially all of the lipoprotein VLDL, as well as a majority of the LDL in the test sample, will form the complex/precipitate. Because the complex formation is 35 much greater between CRP and VLDL and IDL, as compared to between CRP and LDL and HDL (see Fig. 42), in this embodiment, the complex formed by adding exogenous CRP can

be correlated to total VLDL and/or VLDL + IDL levels. When adding additional CRP, the CRP can be isolated or purified CRP or recombinant CRP.

It should be understood that the present invention is 5 useful for detecting complex formation in the absence of adding exogenous lipids to the test sample, or in the absence of adding exogenous lipids to the patient (e.g. intravenous administration of lipids such as Intralipid).

Rather, the present invention is desirable for detecting 10 a patient's own lipoproteins such as VLDL complexed with the patient's own acute phase protein(s) such as CRP. By measuring this "natural" lipoprotein-acute phase protein complex (rather than artificially causing the complex to form due to the addition of exogenous lipids), the test 15 can be a helpful predictor of clinical outcome.

In a further embodiment of the invention the slope of the clot profile and/or the overall change in turbidity (e.g. as measured by optical transmittance or absorbance) can be utilized to diagnose the condition of the patient.

20 More particularly, one or more reagents are added to a test sample from a patient. The test sample should include at least a component of blood from the patient (e.g. plasma or serum could be used). The reagents are capable of causing the formation of the complex in vitro, 25 which complex comprises at least one acute phase protein and at least one lipoprotein, while causing substantially no fibrin polymerization. The formation of the complex is measured over time so as to derive a time-dependent measurement profile. Then the slope and/or overall change 30 in turbidity ("delta") are used to diagnose the condition of the patient (e.g. predict the likelihood of mortality of the patient).

In a still further embodiment of the invention, a method for testing therapeutics (or "test compound") or 35 treatment agents includes providing a human or animal subject whose blood undergoes complex formation and administering a therapeutic to the human or animal subject

whose blood shows evidence of complex formation. Then, a therapeutic is either administered to the subject or added to the test sample *in vitro*, followed by determining whether complex formation is increased, decreased or 5 prevented entirely. If the therapeutic is administered to the patient, it is preferable that it be administered over time and that the complex formation (or lack thereof) be likewise monitored over time.

For the purposes of the foregoing, the terms "test 10 compound" and "therapeutic" refer to an organic compound, drug, or pharmaceutically active agent, particularly one being tested to confirm effectiveness in a clinical trial on a human or animal (preferably mammalian such as dog, cat or rat) subject (rather than an approved therapeutic 15 agent being used to treat a disease in a particular subject). The therapeutic may, in general, be an antibiotic agent, an anti-inflammatory agent, an anti-coagulant agent, a pro-coagulant agent, etc. In addition to clinical trial or drug testing use, the method may also 20 be used in conjunction with an approved therapeutic agent such as those described above to monitor the effectiveness of the therapeutic agent in a particular patient. Thus, if the particular therapeutic is early on discovered to be 25 ineffective for a particular patient, an opportunity is provided to switch the patient to a different therapeutic which may prove to be more effective for that patient.

Table 12 shows CRP, VLDL, Slope 1 and the turbidity changes in 15 patients.

Table 12

Patient #	Turbidity (ΔA405 nm)	Slope $\frac{1}{\times 10^5}$	CRP (μg/mL)	VLDL Cholesterol (mM)	VLDL Apo (B) (mM)	VLDL Total Protein (μg/mL)
1	0.290	185	266	1.320	367.0	553.0
2	0.145	294	398	0.360	87.1	83.1
3	0.062	160	219	0.440	64.2	114.0
4	0.048	198	342	0.297	64.8	78.5
5	0.033	221	294	0.568	143.0	169.0
6	0.095	274	323	0.276	50.8	62.6
7	0.288	361	355	0.850	230.0	310.0
8	0.162	292	314	0.478	94.5	144.0
9	0.401	564	361	0.810	134.0	243.0
10	0.057	240	220	0.329	72.2	79.0
11	0.187	389	387	0.460	113.0	155.0
12	0.143	206	274	0.378	72.5	157.0
13	0.146	314	212	0.554	108.0	134.0
14	0.106	414	274	0.350	104.0	113.0
15	0.021	109	77	0.095	14.4	41.7

VLDL levels were measured 3 ways: 1) Total cholesterol, 2) ELISA for Apo(B), and 3) total protein by the Bradford 5 assay.

Figures 37 through 55 illustrate further features of the present invention.

It is to be understood that the invention described and illustrated herein is to be taken as a preferred example of the same, and that various changes in the methods of the invention may be resorted to, without departing from the spirit of the invention or scope of the claims.

WE CLAIM:

1. A method comprising:
 - 5 a) adding one or more reagents to a test sample from a patient comprising at least part of a blood sample from the patient in order to cause formation of a complex comprising at least one acute phase protein and at least one human lipoprotein, while causing substantially no fibrin polymerization;
 - 10 b) measuring the formation of said complex over time so as to derive a time-dependent measurement profile; and
 - 15 c) determining a slope and/or total change in the time-dependent measurement profile so as to diagnose a condition of the patient.
2. The method according to claim 1, wherein said reagent comprises a metal ion.
20
3. The method according to claim 2, wherein said metal ion is a divalent metal ion.
25
4. The method according to claim 3, wherein said divalent metal ion is a metal ion from the transition elements.
5. The method according to claim 2, wherein said metal ion comprises one or more of calcium, magnesium, manganese, iron or barium.
30
6. The method according to claim 1, wherein a clot inhibitor is provided as part of said reagent or as part of an additional reagent added to said test sample.
35

7. The method according to claim 6, wherein said clot inhibitor comprises one or more of hirudin, heparin, PPACK, I2581, and antithrombin.
- 5 8. The method according to claim 1, wherein the formation of said complex is correlated to the increase probability of death of the patient.
- 10 9. The method according to claim 8, wherein the greater the formation of said complex, the greater the likelihood of death of the patient.
- 15 10. The method according to claim 1, wherein the time dependent measurement profile is an optical transmission profile, and wherein the greater the decrease of optical transmittance through the test sample, the greater the formation of said complex, and the greater the likelihood of mortality of the patient.
- 20 11. The method according to claim 1, wherein said at least one human lipoprotein comprises one or more of chylomicrons or remnants thereof, VLDL, IDL, LDL or HDL, and wherein said at least one acute phase protein comprises CRP and/or SAA.
- 25 12. The method according to claim 11, wherein the diagnosing of the condition of the patient comprises a prediction of the likelihood of mortality of the patient.
- 30 13. The method according to claim 1, wherein said reagent is added to said test sample in the absence of clot inducing reagents.
- 35 14. The method according to claim 1, wherein the formation of the precipitate is measured at

least once after time_0.

15. The method according to claim 14, wherein a single endpoint measurement is made of
5 precipitate formation after time_0.
10. The method according to claim 1, wherein said reagent is capable of causing precipitate formation completely in the absence of fibrin
polymerization.
15. The method according to claim 10, wherein the amount of fibrin polymerization in the method, if any, causes no change in optical transmittance.
20. A method for predicting an increased likelihood of system failure or mortality of a patient, comprising:
 - a) obtaining a blood sample from a patient;
 - b) obtaining plasma or serum from said blood sample;
 - c) adding a reagent capable of inducing the formation of a protein complex comprising at least one lipoprotein and at least one acute phase protein;
 - d) taking one or more measurements of a parameter of the plasma or serum and correlating the measured parameter to complex formation if present;
 - e) correlating the formation of the complex to an increased likelihood of system failure or mortality of the patient.
30. The method according to claim 18, wherein a
35.

plurality of measurements are made after addition of said one or more reagents in order to derive a time-dependent measurement profile.

- 5 20. The method according to claim 18, wherein a single reagent is used prior to taking said measurements.
- 10 21. The method according to claim 18, wherein said measurements are measurements of optical transmission or absorbance through said sample.
- 15 22. The method according to claim 21, wherein said reagent comprises a metal ion.
- 20 23. The method according to claim 22, wherein said metal ion comprises one or more of calcium, magnesium, manganese, iron or barium.
- 25 24. The method according to claim 18, wherein a clot inhibitor is provided as part of said one or more reagents.
- 30 25. The method according to claim 24, wherein said clot inhibitor comprises one or more of hirudin, heparin, PPACK, I2581 or antithrombin.
- 35 26. The method according to claim 18, wherein said one or more measurements are unaffected by clot formation due to lack of fibrin polymerization.
27. The method according to claim 18, wherein the one or more measurements are a plurality of measurements, and wherein a rate of change of said plurality of measurements or a total change is determined, and wherein haemostatic dysfunction is determined based on the

determined total and/or rate of change.

28. The method according to claim 18, wherein said at least one lipoprotein comprises VLDL, IDL and/or LDL, and said at least one acute phase protein comprises SAA and/or CRP.

5

29. The method according to claim 28, wherein a majority of said complex comprises CRP bound to VLDL.

10

30. The method according to claim 18, wherein the prediction of the increased likelihood of system failure or mortality is more accurate than in the absence of steps a) to e).

15

31. The method according to claim 18, wherein steps a) to e) are performed at least once more at a later time in order to determine patient condition regression or progression.

20

32. A method comprising:

25

- a) adding one or more reagents to a test sample comprising at least a component of a blood sample from a patient in order to cause formation of a precipitate comprising an acute phase protein and a lipoprotein;
- b) measuring the precipitate comprising the acute phase protein and the lipoprotein;
- c) adding an inhibiting reagent, before or after adding said one or more precipitate causing reagents, which inhibits at least in part the formation of the precipitate; and
- 30
- d) determining the extent of inhibition

35

of said inhibiting reagent.

33. The method of claim 32, wherein said precipitate inhibiting reagent is added after all or substantially all of the lipoprotein has become associated with acute phase protein so as to form said precipitate.

5

34. The method of claim 32, wherein said precipitate inhibiting reagent is added prior to adding the precipitate causing reagent.

10

35. The method of claim 32, wherein said precipitate inducing reagent is a divalent metal cation.

15

36. The method of claim 35, wherein said precipitate inhibiting reagent comprises one or more of an apolipoprotein capable of binding to CRP, a phosphophorylcholine, , EDTA, sodium citrate, or an antibody capable of binding to a lipoprotein-acute phase protein binding site.

20

37. The method of claim 36, wherein said precipitate inhibiting reagent is capable of inhibiting the association of CRP with chylomicrons or remnants thereof, LDL, VLDL and/or IDL.

25

38. The method of claim 37, wherein the determining of the extent of inhibition is performed over time so as to derive a time-dependent measurement profile.

30

39. The method of claim 38, wherein the measurement over time is a measurement of optical

35

transmittance or absorbance over time.

40. A method comprising:

- 5 a) providing a test sample from a test subject;
- b) adding a reagent to said test sample in order to cause formation of a complex of one or more lipoproteins and one or more acute phase proteins;
- 10 c) measuring the formation of the complex;
- d) correlating the formation of the complex to a concentration of said one or lipoproteins.

15

41. The method of claim 40, wherein said reagent comprises a divalent metal cation and an acute phase protein.

20

42. The method of claim 41, wherein said acute phase protein is CRP.

25

43. The method of claim 41, wherein said one or more lipoproteins is chylomicrons, VLDL and/or IDL.

30

44. The method of claim 41, wherein the formation of the complex and the formation of the additional complex are measured over time so as to provide respective first and second time-dependent measurement profiles.

35

45. The method of claim 40, wherein the measured additional complex and the measured initial complex together are correlated to a total amount of acute phase protein in the test sample.

46. The method of claim 44, wherein the acute phase protein is C-reactive protein.

5 47. The method of claim 40, wherein the measured initial complex is correlated to a likelihood of system failure and/or mortality.

10 48. The method of claim 46, wherein the greater the initial complex measured, the greater the likelihood of system failure and/or mortality.

49. A method for testing the effectiveness of a therapeutic, comprising:

15 a) providing from a test subject a test sample to be tested for complex formation;


b) adding a reagent which causes formation of a complex of acute phase protein and lipoprotein present in said test sample;

c) administering to said test subject a therapeutic;

20 d) repeating steps a) and b); and

e) determining if the amount of complex formed has changed.

A.



B.




FIG. 1






FIG. 2


A.



B.



C.



D.





FIG. 3

**FIG. 4**






FIG. 5






FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20

14/32




FIG. 21




FIG. 22





FIG. 22 (CONT.)




FIG. 23




FIG. 24




FIG. 25




FIG. 26




FIG. 27




FIG. 28




FIG. 29




FIG. 30






FIG. 31

FIG. 32FIG. 33

23/32




FIG. 34






FIG. 35

FIG. 36FIG. 37




FIG. 38




FIG. 39




FIG. 40




FIG. 41

27/32




FIG. 42




FIG. 43




FIG. 44




FIG. 45




FIG. 46




FIG. 47




FIG. 48




FIG. 49




FIG. 50

SEQUENCE LISTING

<110> Fischer, Timothy
Downey, Colin
Nesheim, Mike
Samis, John
Tejidor, Liliana
Toh, Cheng

<120> A METHOD FOR DETECTING A LIPOPROTEIN-ACUTE PHASE PROTEIN COMPLEX AND PREDICTING AN INCREASED RISK OF SYSTEM FAILURE OR MORTALITY

<130> 9250.5CTIP4.WO

<150> US 09/591,642
<151> 2000-06-09

<150> US 09/372,954
<151> 1999-08-12

<150> US 09/244,240
<151> 1999-02-04

<160> 1

<170> PatentIn version 3.0

<210> 1
<211> 10
<212> PRT
<213> Homo sapiens

<220>
<221> UNSURE
<222> (6)..(6)
<223> Amino acid residue unknown.

<400> 1

Gln Thr Asp Met Ser Xaa Lys Ala Phe Val
1 5 10

PATENT COOPERATION TREATY

10/01/9089

PCT

NOTIFICATION OF ELECTION
(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
US Department of Commerce
United States Patent and Trademark
Office, PCT
2011 South Clark Place Room
CP2/5C24
Arlington, VA 22202
ETATS-UNIS D'AMERIQUE
in its capacity as elected Office

Date of mailing (day/month/year) 09 January 2002 (09.01.02)	
International application No. PCT/US01/18611	Applicant's or agent's file reference 9250.5CTIP4.
International filing date (day/month/year) 08 June 2001 (08.06.01)	Priority date (day/month/year) 09 June 2000 (09.06.00)
Applicant FISCHER, Timothy, J. et al	

1. The designated Office is hereby notified of its election made:

in the demand filed with the International Preliminary Examining Authority on:

10 December 2001 (10.12.01)

in a notice effecting later election filed with the International Bureau on:

2. The election was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

BEST AVAILABLE COPY

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer El Mostafa MOUSSAID Telephone No.: (41-22) 338.83.38
---	---

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

10019087

Applicant's or agent's file reference 9250.5CTIP4.	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/US 01/ 18611	International filing date (day/month/year) 08/06/2001	(Earliest) Priority Date (day/month/year) 09/06/2000
Applicant AKZO NOBEL N.V. et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
 - the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).
- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :
 - contained in the international application in written form.
 - filed together with the international application in computer readable form.
 - furnished subsequently to this Authority in written form.
 - furnished subsequently to this Authority in computer readable form.
 - the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
 - the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. **Certain claims were found unsearchable** (See Box I).

3. **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

- the text is approved as submitted by the applicant.
- the text has been established by this Authority to read as follows:

A METHOD FOR DETECTING A LIPOPROTEIN-ACUTE PHASE PROTEIN COMPLEX

5. With regard to the **abstract**,

- the text is approved as submitted by the applicant.
- the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

- as suggested by the applicant.
- because the applicant failed to suggest a figure.
- because this figure better characterizes the invention.

None of the figures.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 32-46

The present application fails to comply with the clarity and conciseness requirements of Article 6 PCT (see also Rule 6.1(a) PCT) to such an extent that a meaningful search is impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear (and concise), namely claims 1-31, 47-49.

The technical problem to be solved by the present invention is the provision of a method of predicting haemostatic dysfunction in a sample. The solution proposed (see examples) is based on the time-dependent measurement profile of the formation of an acute phase protein-human lipoprotein complex, and correlating this profile with the condition in the patient.

Independent claims 32 and 40 are however very vague and relate to unclearly defined methods, which do not appear to be related to the solution of the technical problem above mentioned.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 01/18611

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 G01N33/86 G01N33/92
--

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
--

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, SCISEARCH, EMBASE, CHEM ABS Data
--

C. DOCUMENTS CONSIDERED TO BE RELEVANT
--

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 41291 A (AKZO NOBEL) 19 December 1996 (1996-12-19) the whole document ---	1-31, 47-49
A	DOWNEY, C. ET AL: "Early identification and prognostic implications in disseminated intravascular coagulation through transmittance waveform analysis" THROMBOSIS AND HAEMOSTASIS, vol. 80, no. 1, July 1998 (1998-07), pages 65-69, XP001098607 the whole document ---	1-31, 47-49

<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.
--

<input checked="" type="checkbox"/> Patent family members are listed in annex.
--

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

22 August 2002

Date of mailing of the international search report
--

04/09/2002

Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+31-70) 340-3016
--

Authorized officer

Moreno de Vega, C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/18611

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>BHAKDI, S. ET AL: "Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation" ARTERIOSCLEROSIS, THROMBOSIS AND VASCULAR BIOLOGY, vol. 19, no. 10, October 1999 (1999-10), pages 2348-2354, XP001098610 the whole document</p> <p>---</p>	1-31, 47-49
A	<p>TOH, C. H. ET AL: "THE MECHANISM UNDERLYING THE ATYPICAL CLOT WAVEFORM PROFILE OF DIC IS THROMBIN-INDEPENDENT BUT CALCIUM-DEPENDENT" ABSTRACT FORM EUROPEAN HAEMATOLOGY ASSOCIATION, 25 June 2000 (2000-06-25), page 1 XP002936645 the whole document</p> <p>-----</p>	1-31, 47-49

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/18611

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 9641291	A	19-12-1996	US 5708591 A	13-01-1998
			AT 206226 T	15-10-2001
			AU 711998 B2	28-10-1999
			AU 5984796 A	30-12-1996
			CA 2221712 A1	19-12-1996
			DE 69615556 D1	31-10-2001
			DE 69615556 T2	06-06-2002
			DK 834145 T3	21-01-2002
			EP 0834145 A1	08-04-1998
			ES 2164888 T3	01-03-2002
			JP 11507131 T	22-06-1999
			PT 834145 T	28-03-2002
			US 6321164 B1	20-11-2001
			WO 9641291 A1	19-12-1996
			US 6269313 B1	31-07-2001
			US 2002019706 A1	14-02-2002
			US 6101449 A	08-08-2000